{
  "id": "SQ-LIP-000041",
  "question": "How does lipedema affect health-related quality of life?",
  "question_pt": "Como o lipedema afeta a qualidade de vida relacionada à saúde?",
  "phrasings": [],
  "phrasings_pt": [],
  "knowledge_state": "emerging",
  "tags": [
    "Mental health",
    "Comorbidities"
  ],
  "keywords": [
    "quality of life",
    "well-being",
    "physical functioning",
    "lipedema"
  ],
  "current_answer": "Based on currently indexed evidence, lipedema is consistently associated with substantially reduced health-related quality of life (HRQoL) and elevated psychological burden. The strongest single source — a 2025 systematic review and meta-analysis (moderate GRADE) — found women with lipedema score below population norms across all SF-36/RAND-36 domains, with the largest deficits in energy/fatigue, bodily pain, role-physical, and general health, plus impaired emotional well-being. This pattern is corroborated by numerous cross-sectional cohorts (mostly low GRADE) showing reduced WHOQOL-BREF, SF-36/RAND-36, and EQ-5D-3L scores versus reference populations, with physical and psychological domains most affected. Depression and anxiety are frequently reported: depressive-symptom prevalence (PHQ-8/PHQ-9 ≥10) ranges from roughly 50–59% in several cohorts, and one moderate-GRADE Swiss cohort (n=239) reported anxiety in 64% and low QoL in ~67–72%. Worse QoL correlates strongly with greater depression severity (r up to −0.77) and with pain, symptom severity (leg heaviness, swelling, joint/tissue pain), stigma, appearance-related distress, and reduced mobility. Evidence on disease-stage effects is mixed: some cohorts show worse QoL/depression at advanced stages while two cohorts (including the moderate-GRADE Swiss study) found psychosocial burden largely independent of stage. Two studies indicate symptomatic/psychosocial improvement after liposuction (reduced PHQ-4 depression/anxiety, improved QoL, self-esteem), but these are uncontrolled single-arm designs. Importantly, one BMI-adjusted comparison found disability remained worse in lipedema versus overweight/obese controls, but depression and anxiety did NOT significantly differ after BMI adjustment, suggesting some psychological burden may be shared with obesity rather than lipedema-specific.",
  "current_answer_pt": "Com base nas evidências atualmente indexadas, o lipedema está consistentemente associado a uma qualidade de vida relacionada à saúde (QVRS) substancialmente reduzida e a um elevado ônus psicológico. A fonte isolada mais robusta — uma revisão sistemática e metanálise de 2025 (GRADE moderado) — constatou que mulheres com lipedema pontuam abaixo das normas populacionais em todos os domínios do SF-36/RAND-36, com os maiores déficits em energia/fadiga, dor corporal, função física e saúde geral, além de bem-estar emocional prejudicado. Esse padrão é corroborado por numerosas coortes transversais (em sua maioria GRADE baixo) que mostram escores reduzidos de WHOQOL-BREF, SF-36/RAND-36 e EQ-5D-3L em comparação com populações de referência, com os domínios físico e psicológico mais afetados. Depressão e ansiedade são frequentemente relatadas: a prevalência de sintomas depressivos (PHQ-8/PHQ-9 ≥10) varia de cerca de 50–59% em várias coortes, e uma coorte suíça de GRADE moderado (n=239) relatou ansiedade em 64% e baixa QV em ~67–72%. Pior QV correlaciona-se fortemente com maior gravidade da depressão (r até −0,77) e com dor, gravidade dos sintomas (peso nas pernas, inchaço, dor articular/tecidual), estigma, sofrimento relacionado à aparência e redução da mobilidade. As evidências sobre os efeitos do estágio da doença são mistas: algumas coortes mostram pior QV/depressão em estágios avançados, enquanto duas coortes (incluindo o estudo suíço de GRADE moderado) constataram que o ônus psicossocial é amplamente independente do estágio. Dois estudos indicam melhora sintomática/psicossocial após a lipoaspiração (redução de depressão/ansiedade pelo PHQ-4, melhora da QV e da autoestima), mas são desenhos não controlados de braço único. É importante destacar que uma comparação ajustada pelo IMC constatou que a incapacidade permaneceu pior no lipedema em comparação com controles com sobrepeso/obesidade, mas depressão e ansiedade NÃO diferiram significativamente após o ajuste pelo IMC, sugerindo que parte do ônus psicológico pode ser compartilhada com a obesidade e não ser específica do lipedema.",
  "bottom_line": "Women with lipedema consistently report substantially lower quality of life than the general population across physical, emotional, and social domains, with high rates of depression and anxiety; physical disability appears worse than in people with obesity alone, even after accounting for body weight. Whether lipedema itself independently causes the psychological burden—rather than shared effects of obesity, chronic pain, or stigma—remains unresolved, and no controlled trials confirm that any treatment genuinely improves quality of life.",
  "bottom_line_pt": "Mulheres com lipedema relatam consistentemente qualidade de vida muito inferior à da população geral em domínios físicos, emocionais e sociais, com altas taxas de depressão e ansiedade; a incapacidade física parece pior do que em pessoas com obesidade isolada, mesmo após ajuste pelo peso corporal. Se o lipedema em si causa de forma independente o sofrimento psicológico — ou se isso reflete efeitos compartilhados com obesidade, dor crônica ou estigma — permanece sem resposta, e nenhum ensaio controlado confirma que algum tratamento melhora genuinamente a qualidade de vida.",
  "major_uncertainty": "Nearly all evidence is cross-sectional and self-reported with unknown/unclear risk of bias, precluding causal inference about whether lipedema itself drives reduced QoL and depression versus confounding by obesity, chronic pain, or stigma. The one BMI-adjusted study found no independent effect on depression/anxiety, and meta-analytic estimates carry high heterogeneity (I²=83–93%). Whether interventions (e.g., liposuction) genuinely improve HRQoL remains unconfirmed by controlled trials.",
  "version": "1.1",
  "created": "2026-06-02",
  "updated": "2026-06-02",
  "compiled_by": {
    "model": "anthropic/claude-opus-4.8",
    "label": "Claude Opus 4.8",
    "date": "2026-06-02"
  },
  "outcomes": [
    {
      "outcome": "Overall HRQoL",
      "outcome_pt": "QVRS global",
      "direction": "reduced",
      "confidence": "moderate",
      "disease_modifying": false,
      "note": "Meta-analysis + multiple cohorts: lipedema patients score below population norms across all SF-36/RAND-36 domains.",
      "note_pt": "Metanálise + várias coortes: pacientes com lipedema pontuam abaixo das normas populacionais em todos os domínios SF-36/RAND-36."
    },
    {
      "outcome": "Physical functioning/fatigue/pain",
      "outcome_pt": "Função física/fadiga/dor",
      "direction": "reduced",
      "confidence": "moderate",
      "disease_modifying": false,
      "note": "Largest QoL deficits in energy/fatigue, bodily pain, role-physical; disability worse than BMI-matched controls.",
      "note_pt": "Maiores déficits de QV em energia/fadiga, dor corporal, função física; incapacidade pior que controles pareados por IMC."
    },
    {
      "outcome": "Depression",
      "outcome_pt": "Depressão",
      "direction": "increased",
      "confidence": "low",
      "disease_modifying": false,
      "note": "Frequent elevated depressive symptoms (~50–59% PHQ≥10), but one BMI-adjusted study found no excess vs obese controls.",
      "note_pt": "Sintomas depressivos elevados frequentes (~50–59% PHQ≥10), mas um estudo ajustado por IMC não achou excesso vs obesos."
    },
    {
      "outcome": "Anxiety",
      "outcome_pt": "Ansiedade",
      "direction": "increased",
      "confidence": "low",
      "disease_modifying": false,
      "note": "High anxiety prevalence (e.g. 64% HADS≥8 in moderate-GRADE cohort); not stage-dependent; BMI-adjusted data null.",
      "note_pt": "Alta prevalência de ansiedade (ex.: 64% HADS≥8 em coorte GRADE moderado); independente de estágio; dados ajustados por IMC nulos."
    },
    {
      "outcome": "Emotional well-being / mental QoL",
      "outcome_pt": "Bem-estar emocional / QV mental",
      "direction": "reduced",
      "confidence": "low",
      "disease_modifying": false,
      "note": "Emotional/psychological WHOQOL & SF-36 domains impaired; QoL strongly inversely correlated with depression (r up to -0.77).",
      "note_pt": "Domínios emocional/psicológico do WHOQOL e SF-36 prejudicados; QV fortemente correlacionada inversamente com depressão (r até -0,77)."
    },
    {
      "outcome": "Social functioning / stigma / isolation",
      "outcome_pt": "Função social / estigma / isolamento",
      "direction": "reduced",
      "confidence": "low",
      "disease_modifying": false,
      "note": "Higher stigma and social isolation; stigma correlates negatively with social functioning (r=-0.54) and emotional well-being.",
      "note_pt": "Maior estigma e isolamento social; estigma correlaciona-se negativamente com função social (r=-0,54) e bem-estar emocional."
    },
    {
      "outcome": "QoL improvement after liposuction",
      "outcome_pt": "Melhora da QV após lipoaspiração",
      "direction": "improved",
      "confidence": "low",
      "disease_modifying": false,
      "note": "Uncontrolled single-arm studies: reduced PHQ-4, improved QoL/self-esteem post-op; no controlled trials, symptomatic only.",
      "note_pt": "Estudos não controlados de braço único: redução PHQ-4, melhora QV/autoestima pós-op; sem ensaios controlados, apenas sintomático."
    }
  ],
  "evidence_direction": {
    "supporting": 18,
    "contradicting": 0,
    "other": 1
  },
  "knowledge_freshness": {
    "pct": 81,
    "sources": 21,
    "newest": 2025,
    "oldest": 2016,
    "small_base": false,
    "label": "current evidence base"
  },
  "claims": [
    {
      "id": "SCR-LIP-000167",
      "role": "supporting",
      "statement": "In a cross-sectional study of 43 Czech women with lipedema, 50.9% had moderate-to-severe depressive symptoms (PHQ-9 >=10) and WHOQOL-BREF scores were low across domains (psychological 46.3, physical 50.8), with the psychological domain most affected; specific physical symptoms (shortness of breath, muscle stiffness, appetite problems, fatigue, numbness) were significantly associated with depression severity."
    },
    {
      "id": "SCR-LIP-000168",
      "role": "supporting",
      "statement": "In a cross-sectional study of 354 women with lipedema, 35% met FMS criteria, and those with comorbid FMS had significantly higher anxiety (13.11 vs 9.87) and depression (10.23 vs 8.26) scores and lower SF-12 physical (35.37 vs 42.55) and mental (35.27 vs 40.38) quality-of-life scores (all p<0.001)."
    },
    {
      "id": "SCR-LIP-000169",
      "role": "supporting",
      "statement": "In a study comparing lipedema patients with population controls matched for sex, age and BMI, lipedema patients reported worse self-rated general health, higher rates of self-reported depression (43.6% vs 18.5%, p=0.001) with PHQ-8 depressive symptoms in 89.7% versus 39.3% of controls, more severe pain and pain-related disability, fewer close social contacts, and a strong positive correlation between pain severity and depressive symptoms (rho=0.612, p<0.001)."
    },
    {
      "id": "SCR-LIP-000170",
      "role": "supporting",
      "statement": "In a survey of 98 Polish women with lipedema, all WHOQOL-BREF domains scored below general-population values (physical health 45.4, psychological 46.3, social relationships 50.4, environment 49.6 on 0-100), 59.2% had PHQ-9 scores >=10 indicating possible depression (mean PHQ-9 12.2), and core lipedema symptoms (Factor 1: leg heaviness, joint/tissue/muscle pain, swelling, stiffness) were the only significant predictor of worse quality of life (beta=-0.345, p=0.004, model explaining 23.5% of variance)."
    },
    {
      "id": "SCR-LIP-000171",
      "role": "supporting",
      "statement": "In this scoping review, lipedema patients showed reduced quality of life (EQ-5D-3L 66.1 vs 85 in the Dutch population; WHOQOL-BREF physical/mental domains below midpoint), depression prevalence of 22.7%-42%, 51.1% with mental disorders, and QoL strongly correlated with depression severity (r=-0.75)."
    },
    {
      "id": "SCR-LIP-000173",
      "role": "supporting",
      "statement": "In 329 women with lipedema, lower quality of life (WHOQOL-BREF) was independently predicted by higher depression (PHQ-9 β=-0.36), higher appearance-related distress (DAS-24 β=-0.29), lower mobility (β=0.27) and higher symptom severity, with the final regression model explaining 73% of QoL variance and mean PHQ-9 of 11.87 indicating minor depression."
    },
    {
      "id": "SCR-LIP-000174",
      "role": "supporting",
      "statement": "In a cross-sectional survey of 245 women with lipedema, health-related stigma was significantly higher than in an age-matched general female population (Distress 49.5 vs 17.1–28.7; 65% with moderate/severe distress) and correlated negatively with all RAND-36 quality-of-life domains (strongest for social functioning r=−0.54 and emotional well-being r=−0.50), while greater perceived social support correlated positively with HRQoL."
    },
    {
      "id": "SCR-LIP-000175",
      "role": "supporting",
      "statement": "In a cross-sectional study of 37 women with lipedema versus 36 with lymphedema, lipedema patients showed moderate depression (PHQ-9 mean 10.4) and impaired global quality of life (LYMQOL-Leg 5.47) comparable to lymphedema patients, while lymphedema patients had worse functional status and life satisfaction; in lipedema, longer disease duration correlated with PHQ-9 (r=-0.415, p=0.028) and BMI correlated with functional impairment."
    },
    {
      "id": "SCR-LIP-000177",
      "role": "refines",
      "statement": "Compared with overweight/obese women, women with lipedema showed greater disability (WHO-DAS II domains for mobility, household activities, and social participation remained significantly worse after robust BMI adjustment, e.g. social participation Z=3.15, p=0.002; days with difficulties Z=4.13, p<0.001), but showed NO significant differences in depression (BDI-II median 11 vs 8, p=0.130; HADS-D p=0.474) or anxiety (HADS-A 9.16 vs 8.10, p=0.162), before or after BMI adjustment."
    },
    {
      "id": "SCR-LIP-000178",
      "role": "supporting",
      "statement": "In 44 women with lipedema, median total SF-36 quality of life was 57.4/100 (lowest domains: general health 35, pain 47.5, social functioning 50, energy/fatigue 45), below historical healthy Polish population (61.6) and a prior lipedema cohort (59.3), and SF-36 scores did not differ by BMI or WHtR strata."
    },
    {
      "id": "SCR-LIP-000349",
      "role": "supporting",
      "statement": "In a survey of lipedema patients comparing self-reported stages, more advanced stage (3-4) was associated with higher rates of depression (48.3% vs 34.8%, p<0.001), social isolation (staying home 64.3% vs 44.4%), life dissatisfaction (35.7% vs 22.0%), and loss of mobility, while psychological burden such as inferiority complex (72.8%) and constantly thinking about lipedema (73.4%) was high across all stages."
    },
    {
      "id": "SCR-LIP-000350",
      "role": "supporting",
      "statement": "This narrative review synthesizing 25 references reports that lipedema patients show greater emotional dysregulation and higher anxiety (Al-Wardat: 26 patients vs 26 controls via DERS/HAM-A), significant behavioral disturbances versus overweight/obese controls (Chachaj et al.), depressive/anxious symptoms associated with comorbid fibromialgia (Cagliyan Turk et al.), occupational limitations in 51–73% of respondents (Clarke et al.), and that liposuction significantly reduced depressive symptoms and improved quality of life and body image (Arndt et al.)."
    },
    {
      "id": "SCR-LIP-000351",
      "role": "supporting",
      "statement": "In a systematic review and meta-analysis of cross-sectional cohorts, women with lipedema showed reduced HRQoL across all SF-36/RAND-36 domains versus population norms, with the largest deficits in energy/fatigue (43.50 vs 59.4), bodily pain (51.77 vs 77.4), role physical (51.10 vs 82.4), and general health (49.64 vs 73.1), plus impaired emotional well-being (64.19 vs 73.2) reflecting frequent anxiety/depression."
    },
    {
      "id": "SCR-LIP-000352",
      "role": "supporting",
      "statement": "In a prospective study of lipedema patients undergoing power-assisted liposuction, PHQ-4 total scores fell from 4.47 (mild depression, above population norm) to 2.10 (p<0.001), with anxiety subscale dropping 2.47→0.93 and depression subscale 2.00→1.17, while quality-of-life satisfaction (FLZM health module 45.77→88.00), self-esteem (RSES 29.93→33.33), and emotional stability all improved significantly postoperatively."
    },
    {
      "id": "SCR-LIP-000353",
      "role": "supporting",
      "statement": "In a cross-sectional survey of women with lipedema (n=112), WHOQOL-BREF averaged 3.12 (1-5 scale) and life satisfaction (SWLS) averaged 3.63 (below midpoint), with symptom severity explaining 13.9% of QoL variance; psychological flexibility (AAQ-II β=0.26) and social connectedness (SCS-R β=0.37) independently predicted QoL after controlling for symptom severity, raising explained variance to 44.4%."
    },
    {
      "id": "SCR-LIP-000354",
      "role": "supporting",
      "statement": "In a national Swedish survey of women with lipedema, RAND-36 scores were 25-35 points below the age-matched general female population across all subscales (largest gap in physical role functioning, ~43 points lower in ages 60-79; smallest in emotional well-being, ~10 points), with worse physical and social functioning at higher lipedema stages and a self-reported depression prevalence of 13.5%."
    },
    {
      "id": "SCR-LIP-000355",
      "role": "supporting",
      "statement": "In 511 lipedema patients, PHQ-9 averaged 10.84±6.39 with 54% at risk of moderate-to-severe depression, WHOQOL-BREF global score averaged 60.5±16.02 (lowest in physical 54.54 and psychological 51.91 domains), and quality-of-life impairment correlated with disease stage (r=0.55, p<0.001) and inversely with depression score (r=-0.775, p<0.0001)."
    },
    {
      "id": "SCR-LIP-000356",
      "role": "supporting",
      "statement": "In a survey of lipedema patients, RAND-36 quality of life was significantly lower than the general Dutch female population (59.3 vs 74.9, p<0.001) and EQ-5D-3L was reduced (66.1 vs 85), with 42.0% reporting anxiety/depression and 74.1% reporting pain/discomfort (vs 31.1% in the general population)."
    },
    {
      "id": "SCR-LIP-000357",
      "role": "supporting",
      "statement": "In a Swiss cohort of 239 lipedema patients assessed with validated questionnaires, 64.4% had anxiety (HADS≥8), 23.4% had depression (HADS≥8), and low quality of life was found in 71.5% (PCS-SF36) and 67.4% (MCS-SF36), with none of these psychosocial parameters differing significantly across disease stages (p>0.5)."
    }
  ],
  "references": [
    "DOI:10.3389/fgwh.2025.1629077",
    "DOI:10.1089/lrb.2023.0038",
    "DOI:10.3390/life14030295",
    "DOI:10.1186/s12905-021-01174-y",
    "DOI:10.3390/ijerph181910223",
    "DOI:10.1007/s40519-019-00703-x",
    "DOI:10.1080/13548506.2018.1459750",
    "DOI:10.1080/07399332.2025.2499487",
    "DOI:10.1089/lrb.2024.0117",
    "DOI:10.17219/acem/181146",
    "DOI:10.1186/s12905-025-03834-9",
    "DOI:10.1007/s11136-022-03216-w",
    "DOI:10.12740/app/201427",
    "DOI:10.1177/02683555251410009",
    "DOI:10.1016/j.bjps.2024.02.048",
    "DOI:10.1007/s11136-015-1080-x",
    "DOI:10.1186/s12905-022-02022-3",
    "DOI:10.3390/jcm11102836",
    "DOI:10.21203/rs.3.rs-2705753/v1",
    "DOI:10.1007/s13555-018-0241-6",
    "DOI:10.1371/journal.pone.0319099"
  ],
  "cite": "Scientific Claim Registry. How does lipedema affect health-related quality of life?. SQ-LIP-000041 v1.1; 2026-06-02. https://scientificclaims.org/q/SQ-LIP-000041/v1.1.html",
  "versions": [
    {
      "version": "1.1",
      "date": "2026-06-02",
      "url": "https://scientificclaims.org/q/SQ-LIP-000041/v1.1.html"
    },
    {
      "version": "1.0",
      "date": "2026-06-02",
      "url": "https://scientificclaims.org/q/SQ-LIP-000041/v1.0.html"
    }
  ],
  "url": "https://scientificclaims.org/q/SQ-LIP-000041.html",
  "url_pt": "https://scientificclaims.org/pt/q/SQ-LIP-000041.html",
  "version_url": "https://scientificclaims.org/q/SQ-LIP-000041/v1.1.html",
  "license": "CC-BY-4.0",
  "disclaimer": "Evidence-bounded summary; not medical advice."
}